文献速递组学、生物样本库与精准医学流行病学与生物统计临床试验与 GCP

代谢组学分析揭示哮喘吸入性糖皮质激素治疗导致广泛肾上腺抑制

Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma.
PubMed 文献 · Nat Med · 2022-03-21

该研究利用四个独立队列超过14000人的代谢组学数据,鉴定并独立重复了17种在哮喘患者中显著降低的类固醇代谢物。吸入性糖皮质激素(ICS)治疗与最大幅度的类固醇降低相关,且呈剂量依赖性,低剂量ICS亦可导致显著降低;4年低剂量ICS临床试验证实了该效应。电子病历数据显示ICS治疗哮喘患者全天24小时皮质醇水平显著低于未治疗哮喘患者及无哮喘者,且疲劳和贫血显著增加。

要点

  • 哮喘患者中17种类固醇代谢物水平显著降低,ICS治疗者降低幅度最大且呈剂量依赖性。
  • 4年低剂量ICS临床试验证实ICS治疗可显著降低类固醇水平,低剂量亦可导致显著降低。
  • ICS治疗哮喘患者全天24小时皮质醇水平均显著低于未治疗哮喘患者及无哮喘者。

核心结论

  • 哮喘患者接受ICS治疗导致的肾上腺抑制可能比既往认识更为普遍,代表更大的公共卫生问题。
  • 需要对ICS治疗的哮喘患者进行定期皮质醇监测,以在最小化肾上腺抑制不良反应与利用ICS既定获益之间取得最佳平衡。

研究设计与样本

  • 研究利用四个独立队列超过14000人的代谢组学数据进行分析,并独立重复验证。
  • 通过4年低剂量ICS临床试验确认ICS治疗对类固醇水平的影响。
  • 利用电子病历数据比较ICS治疗哮喘患者、未治疗哮喘患者及无哮喘者的皮质醇水平及疲劳、贫血情况。

主要发现

  • 在哮喘患者中鉴定并独立重复了17种水平显著降低的类固醇代谢物。
  • 所有哮喘患者 regardless of medication use 类固醇水平均降低,但ICS治疗者降低幅度最大。
  • ICS治疗对类固醇水平的影响呈剂量依赖性,低剂量ICS治疗亦导致显著降低。
  • ICS治疗哮喘患者皮质醇水平在整个24小时每日周期内均较未治疗哮喘患者及无哮喘者显著降低。
  • ICS治疗哮喘患者疲劳和贫血较未接受ICS治疗者显著增加。

临床怎么用

  • 作者认为需要对ICS治疗的哮喘患者进行定期皮质醇监测,以在最小化肾上腺抑制不良反应与利用ICS既定获益之间取得最佳平衡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The application of large-scale metabolomic profiling provides new opportunities for realizing the potential of omics-based precision medicine for asthma. By leveraging data from over 14,000 individuals in four distinct cohorts, this study identifies and independently replicates 17 steroid metabolites whose levels were significantly reduced in individuals with prevalent asthma. Although steroid levels were reduced among all asthma cases regardless of medication use, the largest reductions were associated with inhaled corticosteroid (ICS) treatment, as confirmed in a 4-year low-dose ICS clinical trial. Effects of ICS treatment on steroid levels were dose dependent; however, significant reductions also occurred with low-dose ICS treatment. Using information from electronic medical records, we found that cortisol levels were substantially reduced throughout the entire 24-hour daily period in patients with asthma who were treated with ICS compared to those who were untreated and to patients without asthma. Moreover, patients with asthma who were treated with ICS showed significant increases in fatigue and anemia as compared to those without ICS treatment. Adrenal suppression in patients with asthma treated with ICS might, therefore, represent a larger public health problem than previously recognized. Regular cortisol monitoring of patients with asthma treated with ICS is needed to provide the optimal balance between minimizing adverse effects of adrenal suppression while capitalizing on the established benefits of ICS treatment.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Kachroo P, Stewart ID, Kelly RS, et al. Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma. Nat Med. 2022. PMID: 35314841. doi:10.1038/s41591-022-01714-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。